



# Leidos Q1 FY23 Earnings Conference Call

May 2, 2023



# Forward-Looking Statements

Certain statements in this presentation contain or are based on "forward-looking" information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as "expects," "intends," "plans," "anticipates," "believes," "estimates," "guidance" and similar words or phrases. Forward-looking statements in this presentation include, among others, estimates of our future growth and financial and operating performance, including future revenues, adjusted EBITDA margins, diluted EPS (including on a non-GAAP basis) and cash flows provided by operating activities, as well as statements about our business contingency plans, government budgets and the ongoing Continuing Resolution, uncertainties in tax due to new tax legislation or other regulatory developments, the impact of COVID-19 and related actions taken to prevent its spread, our contract awards, strategy, planned investments, sustainability goals and our future dividends, share repurchases, capital expenditures, debt repayments, acquisitions, dispositions and cash flow conversion. These statements reflect our belief and assumptions as to future events that may not prove to be accurate.

Actual performance and results may differ materially from those results anticipated by our guidance and other forward-looking statements made in this presentation depending on a variety of factors, including, but not limited to: developments in the U.S. government defense and non-defense budgets, including budget reductions, sequestration, implementation of spending limits or changes in budgetary priorities, delays in the U.S. government budget process or a government shutdown, or the U.S. government's failure to raise the debt ceiling, which increases the possibility of a default by the U.S. government on its debt obligations, related credit-rating downgrades, or an economic recession; uncertainties in tax due to new tax legislation or other regulatory developments; rising inflationary pressures and fluctuations in interest rates; delays in the U.S. government contract procurement process or the award of contracts and delays or loss of contracts as a result of competitor protests; changes in U.S. government procurement rules, regulations and practices; our compliance with various U.S. government and other government procurement rules and regulations; governmental reviews, audits and investigations of our company; our ability to effectively compete and win contracts with the U.S. government and other customers; our reliance on information technology spending by hospitals/healthcare organizations; our reliance on infrastructure investments by industrial and natural resources organizations; energy efficiency and alternative energy sourcing investments; investments by U.S. government and commercial organizations in environmental impact and remediation projects; the effects of COVID-19 or other health epidemics, pandemics and similar outbreaks may have on our business, financial position, results of operations and/or cash flows; our ability to attract, train and retain skilled employees, including our management team, and to obtain security clearances for our employees; our ability to accurately estimate costs, including cost increases due to inflation, associated with our firm-fixed-price contracts and other contracts; resolution of legal and other disputes with our customers and others or legal or regulatory compliance issues; cybersecurity, data security or other security threats, system failures or other disruptions of our business; our compliance with international, federal, state and local laws and regulations regarding privacy, data security, protection, storage, retention, transfer and disposal, technology protection and personal information; the damage and disruption to our business resulting from natural disasters and the effects of climate change; our ability to effectively acquire businesses and make investments; our ability to maintain relationships with prime contractors, subcontractors and joint venture partners; our ability to manage performance and other risks related to customer contracts; the failure of our inspection or detection systems to detect threats; the adequacy of our insurance programs, customer indemnifications or other liability protections designed to protect us from significant product or other liability claims, including cybersecurity attacks; our ability to manage risks associated with our international business; our ability to comply with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act of 2010 and similar worldwide anti-corruption and anti-bribery laws and regulations; our ability to protect our intellectual property and other proprietary rights by third parties of infringement, misappropriation or other violations by us of their intellectual property rights; our ability to prevail in litigation brought by third parties of infringement, misappropriation or other violations by us of their intellectual property rights; our ability to declare or increase future dividends based on our earnings, financial condition, capital requirements and other factors, including compliance with applicable law and our agreements; our ability to grow our commercial health and infrastructure businesses, which could be negatively affected by budgetary constraints faced by hospitals and by developers of energy and infrastructure projects; our ability to successfully integrate acquired businesses; and our ability to execute our business plan and long-term management initiatives effectively and to overcome these and other known and unknown risks that we face.

These are only some of the factors that may affect the forward-looking statements contained in this presentation. For further information concerning risks and uncertainties associated with our business, please refer to the filings we make from time to time with the U.S. Securities and Exchange Commission ("SEC"), including the "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Legal Proceedings" sections of our latest Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, all of which may be viewed or obtained through the Investor Relations section of our website at [www.leidos.com](http://www.leidos.com).

All information in this presentation is as of May 2, 2023. Leidos expressly disclaims any duty to update the guidance or any other forward-looking statement provided in this presentation to reflect subsequent events, actual results or changes in Leidos' expectations. Leidos also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.

# Non-GAAP Financial Measures

This presentation includes certain non-GAAP financial measures, such as organic growth, non-GAAP operating income, non-GAAP operating margin, non-GAAP effective tax rate, non-GAAP diluted earnings per share (EPS), adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted EBITDA margin, non-GAAP free cash flow and non-GAAP free cash conversion.

These are not measures of financial performance under generally accepted accounting principles in the U.S. and, accordingly, these measures should not be considered in isolation or as a substitute for the comparable GAAP measures and should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP.

Management believes that these non-GAAP measures provide another measure of Leidos' results of operations and financial condition, including its ability to comply with financial covenants. These non-GAAP measures are frequently used by financial analysts covering Leidos and its peers. Leidos' computation of its non-GAAP measures may not be comparable to similarly titled measures reported by other companies, thus limiting their use for comparability.

Leidos does not provide a reconciliation of forward-looking adjusted EBITDA margins or non-GAAP diluted EPS to GAAP net income, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Because certain deductions for non-GAAP exclusions used to calculate projected net income may vary significantly based on actual events, Leidos is not able to forecast on a GAAP basis with reasonable certainty all deductions needed in order to provide a GAAP calculation of projected net income at this time. The amounts of these deductions may be material and, therefore, could result in projected GAAP net income and diluted EPS being materially less than projected adjusted EBITDA margins and non-GAAP diluted EPS.

A reconciliation between all non-GAAP measures used in this presentation to the most directly comparable GAAP measure is contained in the appendix.

# CEO Key Messages

1

## Strong revenue growth—above guidance, in line with multi-year targets

- Record revenues on YoY growth of 6% with growth across all three segments
- Organic revenue growth over 5%, led by Civil and Health segments
- Earnings and cash performance will build momentum throughout the year

2

## Deploying capital to create shareholder value

- Balanced, consistent approach to capital allocation
- Returned \$93M to shareholders, including \$25M open market repurchases
- Expect to achieve gross leverage ratio of 3 times by the end of the year

3

## Business Development momentum sets stage for continued growth

- Net book-to-bill ratio of 0.8x, led by strong bookings from the intel portfolio
- Tremendous opportunity with \$29.2B awaiting adjudication
- Backlog of \$35.1B, \$8.3B funded up 17% YoY


4

## Investing in our people and building a market leader


- Over 2,500 hires—increased headcount 7% YoY
- Voluntary attrition has dropped down to pre-pandemic levels
- Focus on career development and building relationships with managers

# Q1 FY23 Results: Income Statement


## Revenues (M)




## Adjusted EBITDA Margin (%)



## Non-GAAP Diluted EPS



# Q1 FY23 Results: Reporting Segments



# Q1 FY23 Results: Cash Flow / Balance Sheet

<b>Cash Flow Generation</b>	<p>Cash flow generation depressed based on one-time events</p> <ul style="list-style-type: none"> <li>▪ Operating cash flow <span style="float: right;">\$(98)M</span></li> <li>▪ Non-GAAP free cash flow <span style="float: right;">\$(137)M</span></li> <li>▪ Tax payments from prior year activities <span style="float: right;">\$191M</span></li> </ul>
<b>Capital Deployment</b>	<p>Following balanced long-term approach to capital deployment</p> <ul style="list-style-type: none"> <li>▪ Total return to shareholders <span style="float: right;">\$93M</span></li> <li>▪ Open market share repurchase <span style="float: right;">\$25M</span></li> <li>▪ CapEx &amp; net debt repayment (incl issuance costs) <span style="float: right;">\$14M</span></li> </ul>
<b>Balance Sheet</b>	<p>Increased financial flexibility through debt refinance and extension</p> <ul style="list-style-type: none"> <li>▪ Strong liquidity <span style="float: right;">&gt;\$1B</span></li> <li>▪ Total debt <span style="float: right;">\$5.0B</span></li> <li>▪ Leverage ratio (net) <span style="float: right;">3.2x</span></li> <li>▪ Leverage ratio (gross) <span style="float: right;">3.4x</span></li> </ul>

# 2023 Guidance

Measure	FY23 Guidance
Revenues (billions)	\$14.7 - \$15.1
Adjusted EBITDA Margin	10.3% - 10.5%
Non-GAAP Diluted EPS	\$6.40 - \$6.80
Cash Flows Provided by Operating Activities (millions)	at or above \$700

## Key Assumptions:

- Continuing Resolution for GFY23 in place through 12/31/23 with no Government shutdown
- Customer payment and outlay practices remain consistent with historical experience
- Procurement schedules are not further extended or cancelled beyond our present forecast
- Protest delays are not excessive in relation to current experience
- No major disruptions from new COVID variants
- Supply chain shortages do not worsen, and we are able to meet the majority of customer demands for technology products



# Appendix: Non-GAAP Reconciliations

# Organic Growth

<i>(in millions, except growth rates)</i>	Q1 FY23	Q1 FY22	Percent Change
<b>Defense Solutions</b>			
Revenues, as reported	\$ 2,112	\$ 2,049	3 %
Acquisition and divestiture revenues <sup>(1)</sup>	30	4	
Organic revenues	\$ 2,082	\$ 2,045	2 %
<b>Civil</b>			
Revenues, as reported	\$ 877	\$ 795	10 %
<b>Health</b>			
Revenues, as reported	\$ 710	\$ 650	9 %
<b>Total Operations</b>			
Revenues, as reported	\$ 3,699	\$ 3,494	6 %
Acquisition and divestiture revenues <sup>(1)</sup>	30	4	
Organic revenues	\$ 3,669	\$ 3,490	5 %

*Note:*

1. Current period acquisition and divestiture revenues reflect revenues for 12 months from closing of an acquisition; year-ago acquisition and divestiture revenues reflect revenues from assets subsequently divested.

# Non-GAAP Income Metrics

(in millions, except per share amounts)	Three Months Ended March 31, 2023				Three Months Ended April 1, 2022			
	As reported	Acquisition, integration and restructuring costs <sup>(1)</sup>	Amortization of acquired intangibles <sup>(2)</sup>	Non-GAAP results	As reported	Acquisition, integration and restructuring costs <sup>(1)</sup>	Amortization of acquired intangibles <sup>(2)</sup>	Non-GAAP results
<b>Operating income</b>	\$ 265	\$ 3	\$ 52	\$ 320	\$ 271	\$ 3	\$ 58	\$ 332
Non-operating expense, net	(58)	—	—	(58)	(49)	—	—	(49)
<b>Income before income taxes</b>	<b>207</b>	<b>3</b>	<b>52</b>	<b>262</b>	<b>222</b>	<b>3</b>	<b>58</b>	<b>283</b>
Income tax expense <sup>(3)</sup>	(43)	(1)	(13)	(57)	(45)	(1)	(14)	(60)
<b>Net income</b>	<b>164</b>	<b>2</b>	<b>39</b>	<b>205</b>	<b>177</b>	<b>2</b>	<b>44</b>	<b>223</b>
Less: net income attributable to non-controlling interest	2	—	—	2	2	—	—	2
<b>Net income attributable to Leidos common stockholders</b>	<b>\$ 162</b>	<b>\$ 2</b>	<b>\$ 39</b>	<b>\$ 203</b>	<b>\$ 175</b>	<b>\$ 2</b>	<b>\$ 44</b>	<b>\$ 221</b>
Diluted EPS attributable to Leidos common stockholders	\$ 1.17	\$ 0.01	\$ 0.28	\$ 1.47	\$ 1.25	\$ 0.01	\$ 0.31	\$ 1.58
Diluted shares	138	138	138	138	140	140	140	140
<b>Income before income taxes</b>	<b>207</b>	<b>3</b>	<b>52</b>	<b>262</b>	<b>222</b>	<b>3</b>	<b>58</b>	<b>283</b>
Depreciation expense	30	—	—	30	26	—	—	26
Amortization of intangibles	52	—	(52)	—	59	—	(58)	1
Interest expense, net	54	—	—	54	48	—	—	48
<b>EBITDA</b>	<b>\$ 343</b>	<b>\$ 3</b>	<b>\$ —</b>	<b>\$ 346</b>	<b>\$ 355</b>	<b>\$ 3</b>	<b>\$ —</b>	<b>\$ 358</b>
EBITDA margin <sup>(4)</sup>	9.3 %			9.4 %	10.2 %			10.2 %

## Notes:

1. Acquisition, integration, lease termination and severance costs related to the Company's acquisitions
2. Amortization of the fair value of the acquired intangible assets
3. Tax impact of non-GAAP items calculated using estimated statutory tax rate
4. EBITDA divided by revenues (slide 5)

# Segment Non-GAAP Operating Income

## Three Months Ended March 31, 2023

<i>(in millions)</i>	Operating income (loss)	Acquisition, integration and restructuring costs	Amortization of acquired intangibles	Non-GAAP operating income (loss)	Non-GAAP operating margin <sup>(1)</sup>
Defense Solutions	\$ 147	\$ —	\$ 30	\$ 177	8.4 %
Civil	40	—	16	56	6.4 %
Health	107	—	6	113	15.9 %
Corporate	(29)	3	—	(26)	NM <sup>(2)</sup>
<b>Total</b>	<b>\$ 265</b>	<b>\$ 3</b>	<b>\$ 52</b>	<b>\$ 320</b>	<b>8.7 %</b>

## Three Months Ended April 1, 2022

<i>(in millions)</i>	Operating income (loss)	Acquisition, integration and restructuring costs	Amortization of acquired intangibles	Non-GAAP operating income (loss)	Non-GAAP operating margin <sup>(1)</sup>
Defense Solutions	\$ 133	\$ —	\$ 33	\$ 166	8.1 %
Civil	43	—	18	61	7.7 %
Health	118	—	7	125	19.2 %
Corporate	(23)	3	—	(20)	NM <sup>(2)</sup>
<b>Total</b>	<b>\$ 271</b>	<b>\$ 3</b>	<b>\$ 58</b>	<b>\$ 332</b>	<b>9.5 %</b>

*Notes:*

1. Non-GAAP operating income divided by revenues (slides 5 and 6)
2. Not meaningful

# Non-GAAP Free Cash Flow

<i>(in millions, except conversion ratio)</i>	Three Months Ended	
	March 31, 2023	April 1, 2022
Net cash (used in) provided by operating activities	\$ (98)	\$ 93
Payments for property, equipment and software	(39)	(28)
Non-GAAP free cash flow	<b>\$ (137)</b>	<b>\$ 65</b>
Net income attributable to Leidos common stockholders	\$ 162	\$ 175
Acquisition, integration and restructuring costs	2	2
Amortization of acquired intangibles	39	44
Non-GAAP net income attributable to Leidos common stockholders	<b>\$ 203</b>	<b>\$ 221</b>
<i>Operating cash flow conversion ratio<sup>(1)</sup></i>	<b>(60)%</b>	53 %
<i>Non-GAAP free cash flow conversion ratio<sup>(2)</sup></i>	<b>(67)%</b>	29 %

*Notes:*

1. Net cash provided by operating activities divided by net income attributable to Leidos common stockholders
2. Free cash flow divided by non-GAAP net income attributable to Leidos common stockholders